Bioinnovations Institute
Natick, MA
- UEI
- Y2V4RA3FU7C5
- CAGE
- 9FS08
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 17 Erie Dr, Natick, MA 01760, USA
- Website
- bioinnovationsinstitute.org
- Founded
- 2022
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | HU00012520036 | $1,240,766 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | HU00012420063 | $1,258,175 | |
| The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | HU00012320102 | $1,244,729 |
Similar vendors
About the company
Bioinnovations Institute, a nonprofit research organization based in Natick, Massachusetts, operates exclusively as a federal grant sub-recipient, delivering specialized biomedical research and nanotoxicology expertise to the Department of Defense through subawards under the Henry M. Jackson Foundation for the Advancement of Military Medicine.
The institute's federal footprint is narrow but focused. All three recent awards (2023–2025) flow through the Jackson Foundation as the prime grantee, with DOD Uniformed Services University of the Health Sciences as the sole customer agency represented across $3.7 million in combined obligated dollars. Bioinnovations holds no prime federal contract vehicles and no prime grant awards; its role is entirely as a specialized technical subcontractor on military medical research initiatives.
The institute's capability portfolio centers on characterization and bioprocessing of airborne toxic metal-containing nanoparticles in warfighter brain tissue, nanotoxicology, ultrastructural analysis, and biomedical imaging of inflammatory mechanisms in neurosensory cells. Named scientists at Bioinnovations — Uschi Graham, Gunter Oberdorster, and Rick Rogers — serve as subject-matter experts in exogenous particulate bioprocessing and nanoparticle toxicology. Work history includes established relationships with researchers at Harvard University, the University of Kentucky, and the University of Rochester.
Recent subaward work includes a September 2023 Cancer Moonshot 2 project tracking military exposures and toxin history in service members (PROMETHEUS initiative), a July 2024 subaward under the APOLLO cancer research award supporting preliminary data for identification and characterization of inhaled toxic metal-containing nanoparticles in Central Nervous System tissues from deceased service members, and a September 2025 subaward continuing characterization of airborne nano-sized particulates across multiple brain regions (olfactory bulbs, distal tract, amygdala, cerebellum) to correlate nanoparticles with neurodegenerative disease or glioblastoma. Activity is sporadic — one award per calendar year — with no announced recompete cliff or vehicle diversity beyond the Jackson Foundation relationship.
Quick answers
Is Bioinnovations Institute registered in SAM.gov?
Yes. Bioinnovations Institute's SAM.gov registration is active through August 14, 2027.
On GovTribe
See Bioinnovations Institute's full federal record
- Similar vendors